BeOne Medicines (BEIGF) Notes Payables (2017 - 2025)
BeOne Medicines' (BEIGF) quarterly Notes Payables came in at $813.3 million in Q3 2025, down 4.49% quarter-over-quarter from $851.5 million in Q4 2024.
Powered by 
Analysis
BeOne Medicines (BEIGF) Notes Payables (2017 - 2025) Analysis & Trends
BeOne Medicines (BEIGF) has reported Notes Payables for 4 consecutive years, with $813.3 million the latest figure, recorded in Q3 2025.
- On a quarterly basis, Notes Payables changed N/A year-over-year to $813.3 million in Q3 2025; TTM through Sep 2025 was $813.3 million, a N/A change from a year earlier, with the FY2024 full-year figure at $851.5 million, changed N/A from the prior year.
- Notes Payables was $813.3 million for Q3 2025 at BeOne Medicines, down from $851.5 million in the prior quarter.
- Over five years, Notes Payables peaked at $851.5 million in Q4 2024 and troughed at $813.3 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.71 Bn | 625.95 Bn | 17.26 Bn |
| 2 | AbbVie | 442.22 Bn | 435.65 Bn | 12.70 Bn |
| 3 | Merck | 366.92 Bn | 359.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.90 Bn | 259.21 Bn | 11.24 Bn |
| 5 | Pfizer | 159.20 Bn | 147.50 Bn | 10.94 Bn |
| 6 | Sanofi | 52.44 Bn | 45.06 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.11 Bn | 44.11 Bn | - |
| 8 | Incyte | 25.38 Bn | 20.85 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.50 Bn | 18.84 Bn | 683.80 Mn |
| 10 | BeOne Medicines | 2.48 Bn | -2.62 Bn | 1.53 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 813.30 Mn |
| Dec 31, 2024 | 851.53 Mn |
| Dec 31, 2020 | 335.02 Mn |
| Mar 31, 2017 | 2.47 Mn |